ArticleFrontiers in bioinformatics2026
Systems-level identification of conserved molecular drivers underlying the progression of alcoholic hepatitis and alcoholic cirrhosis and their therapeutic modulation by S-adenosyl-L-methionine.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alcohol-associated liver disease (ALD) encompasses a progressive spectrum of hepatic injury, with alcoholic hepatitis (AH) and alcoholic cirrhosis (AC) representing clinically severe and mechanistically interconnected stages. Despite significant disease burden, therapeutic strategies targeting core molecular drivers of disease progression remain limited. Identifying conserved regulatory determinants across AH and AC may provide a rational framework for mechanism-driven therapeutic intervention. S-adenosyl-L-methionine (SAMe), a key metabolic intermediate involved in methylation and redox homeostasis, has shown hepatoprotective potential; however, its direct molecular targets in ALD remain poorly characterized. Methodology: An integrative Results: This integrative analysis identified 826 shared DEGs enriched in pathways associated with intracellular signalling, transcriptional regulation and extracellular matrix (ECM) organization. Network analysis revealed TGFB1, COL1A2, ESR1, PDGFRA, LUM and BCL2 as central hub genes. Molecular docking demonstrated favourable binding interactions of SAMe with these targets, with TGFB1 exhibiting the highest binding affinity (-7.0 Kcal/mol). MD simulations confirmed stable conformational dynamics of SAMe-bound complexes, particularly TGFB1, characterized by reduced structural fluctuations, increased compactness and sustained hydrogen bonding. Binding free energy analysis further supported the thermodynamic stability of these interactions, with the TGFB1-SAMe complex showing the most favourable energy profile. Discussion: Collectively, these findings identify conserved molecular signatures linking AH and AC and suggest potential molecular interactions between SAMe and key regulatory proteins implicated in disease progression. By integrating transcriptomic, network and structural analyses, this study provides a systems-level framework for understanding the molecular landscape of ALD and offers a basis for future experimental studies aimed at evaluating therapeutic strategies targeting shared disease determinants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.